• TRAX share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • Price change

    The price of TRAX shares has decreased $0.60 since the market last closed. This is a 1.53% drop.

  • Last closed at $38.60.

    The stock has since risen $0.10 in pre-market trading.

Key terms

About TRAX

First Tracks Biotherapeutics, Inc. engages in the research and development of immunology therapeutics for autoimmune and inflammatory diseases. It focuses on clinical-stage programs for rosnilimab, ANB033 and ANB101. The company is headquartered in San Diego, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
  • Market cap: $1.38B

    A market capitalization between $300 million and $2 billion places TRAX in the small capitalization category.

Key terms

Smart score

Latest TRAX news

Sep 18, 2026 6:05am ET First Tracks Biotherapeutics initiated with an Outperform at Evercore ISI by TipRanks Sep 16, 2026 5:00am ET First Tracks Biotherapeutics initiated with a Buy at Guggenheim by TipRanks Sep 04, 2026 10:05pm ET Major Insider Move Shakes Up First Tracks Biotherapeutics Inc. by TipRanks Sep 03, 2026 9:10am ET Analysts Offer Insights on NA Companies: First Tracks Biotherapeutics Inc (TRAX) and G-III Apparel Group (GIII) by TipRanks Sep 03, 2026 6:15am ET Analyst Reiterates Buy on TRAX as IL-15/CD122 Data De-Risk Celiac Program; $57 Price Target Maintained by TipRanks Sep 03, 2026 4:36am ET First Tracks Biotherapeutics Inc (TRAX) Receives a Rating Update from a Top Analyst by TipRanks Aug 27, 2026 7:56am ET Piper Sandler Sticks to Its Buy Rating for First Tracks Biotherapeutics Inc (TRAX) by TipRanks Aug 20, 2026 8:07am ET J.P. Morgan Reaffirms Their Buy Rating on First Tracks Biotherapeutics Inc (TRAX) by TipRanks Aug 20, 2026 7:20am ET Analysts Offer Insights on NA Companies: Arcturus Therapeutics (ARCT), EquipmentShare.com, Inc. (EQPT) and First Tracks Biotherapeutics Inc (TRAX) by TipRanks Aug 17, 2026 4:42am ET First Tracks Biotherapeutics reports Q2 EPS (95c), consensus (80c) by TipRanks Aug 17, 2026 4:31am ET First Tracks Biotherapeutics price target raised to $65 from $48 at Barclays by TipRanks Aug 17, 2026 4:26am ET First Tracks price target raised to $57 from $44 at H.C. Wainwright by TipRanks Aug 17, 2026 4:14am ET First Tracks Biotherapeutics price target raised to $95 from $54 at Piper Sandler by TipRanks Aug 13, 2026 7:56am ET First Tracks Biotherapeutics Inc (TRAX) Gets a Buy from UBS by TipRanks Aug 13, 2026 7:10am ET Analysts Offer Insights on NA Companies: Cerebras Systems, Inc. Class A (CBRS), CitroTech (CITR) and First Tracks Biotherapeutics Inc (TRAX) by TipRanks Aug 13, 2026 6:30am ET Analysts Offer Insights on NA Companies: First Tracks Biotherapeutics Inc (TRAX), BETA Technologies, Inc. Class A (BETA) and Cerebras Systems, Inc. Class A (CBRS) by TipRanks Aug 13, 2026 4:25am ET Barclays Sticks to Its Buy Rating for First Tracks Biotherapeutics Inc (TRAX) by TipRanks Aug 10, 2026 3:55pm ET First Tracks Biotherapeutics management to meet with Piper Sandler by TipRanks Aug 10, 2026 9:20am ET First Tracks Biotherapeutics price target raised to $65 from $45 at UBS by TipRanks Aug 10, 2026 9:17am ET First Tracks Biotherapeutics Inc (TRAX) Gets a Buy from UBS by TipRanks Jul 28, 2026 10:05am ET Wedbush Remains a Buy on First Tracks Biotherapeutics Inc (TRAX) by TipRanks Jul 28, 2026 8:01am ET First Tracks Biotherapeutics price target raised to $60 from $30 at Wedbush by TipRanks Jul 28, 2026 6:15am ET First Tracks Biotherapeutics price target raised to $55 from $30 at Wells Fargo by TipRanks Jul 28, 2026 3:35am ET First Tracks Biotherapeutics Inc (TRAX) Gets a Buy from Wells Fargo by TipRanks Jul 27, 2026 12:55pm ET First Tracks Biotherapeutics: Buy Rating Reaffirmed with Unchanged $44 Price Target on ANB033 CD122-Targeting Upside and Acquisition Potential by TipRanks Jul 27, 2026 12:05pm ET After Forte acquisition, H.C. Wainwright says First Tracks could be target by TipRanks Jul 21, 2026 6:20am ET First Tracks Biotherapeutics price target raised to $48 from $40 at Barclays by TipRanks Jul 21, 2026 5:01am ET Analysts Offer Insights on NA Companies: First Tracks Biotherapeutics Inc (TRAX) and Medacta Group SA (OtherMEDGF) by TipRanks Jul 20, 2026 7:27am ET Piper Sandler Remains a Buy on First Tracks Biotherapeutics Inc (TRAX) by TipRanks Jul 10, 2026 9:15am ET First Tracks Biotherapeutics Inc (TRAX) Gets a Buy from UBS by TipRanks Jul 10, 2026 7:15am ET J.P. Morgan Remains a Buy on First Tracks Biotherapeutics Inc (TRAX) by TipRanks
Aug 26, 2026 4:15pm ET First Tracks Biotherapeutics Announces Participation in September Investor Conferences by GlobeNewswire Aug 12, 2026 4:15pm ET First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update by GlobeNewswire

TRAX Financials

1-year income & revenue

  • TRAX total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • TRAX net income: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • TRAX earnings per share: currently unavailable. Sorry, we currently don't have enough data to create an insight.

Key terms

TRAX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

TRAX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range
  • How competitors are chosen

    TRAX's competitors are included in the Health Technology sector and Biotechnology group

  • Market cap: $1.38B

    A market capitalization between $300 million and $2 billion places TRAX in the small capitalization category.

Key terms

Latest investing news